Conjugated metallothionein-carbon-doxorubicin nanotransporter for targeted breast cancer therapy.
(2018)
Presentation / Conference Contribution
SKALIČKOVÁ, S., KEPINSKA, M., LOFFELMANN, M., UHLÍŘOVÁ, D., GARGULÁK, M., DOČEKALOVÁ, M., HOSNEDLOVÁ, B., RUTTKAY-NEDECKÝ, B., MILNEROWICZ, H., FERNANDEZ, C. and KIZEK, R. 2018. Conjugated metallothionein-carbon-doxorubicin nanotransporter for targeted breast cancer therapy. In Proceedings of 10th Nanomaterials international conference 2018 (NANOCON 2018): research and application, 17-19 October 2018, Brno, Czech Republic. Ostrava: Tanger Ltd [online], pages 342-347. Available from: https://www.confer.cz/nanocon/2018/download/193-metallothionein-fullerene-doxorubicin-nanotransporter-conjugates-for-targeted-breast-cancer-therapy.pdf
Metalothionein (MT) is a polypeptide of molecular weight in the range of 6-10 kDa. MT typically contains 60 to 68 amino acid residues. MT is characterized by its unique content of metal ions as well as its sulfur content. Higher MT levels were observ... Read More about Conjugated metallothionein-carbon-doxorubicin nanotransporter for targeted breast cancer therapy..